<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<html>
 <body>
  <pubmedarticleset>
   <pubmedarticle>
    <medlinecitation indexingmethod="Automated" owner="NLM" status="MEDLINE">
     <pmid version="1">
      32233755
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       08
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       08
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        2047-9980
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         9
        </volume>
        <issue>
         7
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          04
         </month>
         <day>
          07
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of the American Heart Association
       </title>
       <isoabbreviation>
        J Am Heart Assoc
       </isoabbreviation>
      </journal>
      <articletitle>
       Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
      </articletitle>
      <pagination>
       <medlinepgn>
        e016219
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1161/JAHA.120.016219
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Guo
        </lastname>
        <forename>
         Junyi
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Cardiology Department of Internal Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Huang
        </lastname>
        <forename>
         Zheng
        </forename>
        <initials>
         Z
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Gastroenterology Department of Internal Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lin
        </lastname>
        <forename>
         Li
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Cardiology Department of Internal Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lv
        </lastname>
        <forename>
         Jiagao
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Cardiology Department of Internal Medicine Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D013485">
        Research Support, Non-U.S. Gov't
       </publicationtype>
       <publicationtype ui="D016420">
        Comment
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        01
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       J Am Heart Assoc
      </medlineta>
      <nlmuniqueid>
       101580524
      </nlmuniqueid>
      <issnlinking>
       2047-9980
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D057911">
        Angiotensin Receptor Antagonists
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <commentscorrectionslist>
      <commentscorrections reftype="CommentOn">
       <refsource>
        J Am Heart Assoc. 2020 Apr 7;9(7):e016509
       </refsource>
       <pmid version="1">
        32233753
       </pmid>
      </commentscorrections>
     </commentscorrectionslist>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D057911">
        Angiotensin Receptor Antagonists
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D002318">
        Cardiovascular Diseases
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D017934">
        Coronavirus
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
      </meshheading>
     </meshheadinglist>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="Y">
       ACEI/ARB
      </keyword>
      <keyword majortopicyn="Y">
       COVID‐19
      </keyword>
      <keyword majortopicyn="Y">
       SARS‐CoV‐2
      </keyword>
      <keyword majortopicyn="Y">
       angiotensin‐converting enzyme 2
      </keyword>
      <keyword majortopicyn="Y">
       cardiovascular disease
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        3
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        3
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        9
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32233755
      </articleid>
      <articleid idtype="doi">
       10.1161/JAHA.120.016219
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
     <pmid version="1">
      32269893
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       11
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Print">
        2168-8184
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         12
        </volume>
        <issue>
         4
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          06
         </day>
        </pubdate>
       </journalissue>
       <title>
        Cureus
       </title>
       <isoabbreviation>
        Cureus
       </isoabbreviation>
      </journal>
      <articletitle>
       A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19).
      </articletitle>
      <pagination>
       <medlinepgn>
        e7560
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.7759/cureus.7560
      </elocationid>
      <abstract>
       <abstracttext>
        Coronavirus disease 2019 (COVID-19) is a declared global pandemic. There are multiple parameters of the clinical course and management of the COVID-19 that need optimization. A hindrance to this development is the vast amount of misinformation present due to scarcely sourced manuscript preprints and social media. This literature review aims to presents accredited and the most current studies pertaining to the basic sciences of SARS-CoV-2, clinical presentation and disease course of COVID-19, public health interventions, and current epidemiological developments. The review on basic sciences aims to clarify the jargon in virology, describe the virion structure of SARS-CoV-2 and present pertinent details relevant to clinical practice. Another component discussed is the brief history on the series of experiments used to explore the origins and evolution of the phylogeny of the viral genome of SARS-CoV-2. Additionally, the clinical and epidemiological differences between COVID-19 and other infections causing outbreaks (SARS, MERS, H1N1) are elucidated. Emphasis is placed on evidence-based medicine to evaluate the frequency of presentation of various symptoms to create a stratification system of the most important epidemiological risk factors for COVID-19. These can be used to triage and expedite risk assessment. Furthermore, the limitations and statistical strength of the diagnostic tools currently in clinical practice are evaluated. Criteria on rapid screening, discharge from hospital and discontinuation of self-quarantine are clarified. Epidemiological factors influencing the rapid rate of spread of the SARS-CoV-2 virus are described. Accurate information pertinent to improving prevention strategies is also discussed. The penultimate portion of the review aims to explain the involvement of micronutrients such as vitamin C and vitamin D in COVID19 treatment and prophylaxis. Furthermore, the biochemistry of the major candidates for novel therapies is briefly reviewed and a summary of their current status in the clinical trials is presented. Lastly, the current scientific data and status of governing bodies such as the Center of Disease Control (CDC) and the WHO on the usage of controversial therapies such as angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs) (Ibuprofen), and corticosteroids usage in COVID-19 are discussed. The composite collection of accredited studies on each of these subtopics of COVID-19 within this review will enable clarification and focus on the current status and direction in the planning of the management of this global pandemic.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020, Kakodkar et al.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Kakodkar
        </lastname>
        <forename>
         Pramath
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Medicine, National University of Ireland Galway, Galway, IRL.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kaka
        </lastname>
        <forename>
         Nagham
        </forename>
        <initials>
         N
        </initials>
        <affiliationinfo>
         <affiliation>
          Medicine, National University of Ireland Galway, Galway, IRL.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Baig
        </lastname>
        <forename>
         M N
        </forename>
        <initials>
         MN
        </initials>
        <affiliationinfo>
         <affiliation>
          Orthopaedics, University Hospital Galway, Galway, IRL.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Cureus
      </medlineta>
      <nlmuniqueid>
       101596737
      </nlmuniqueid>
      <issnlinking>
       2168-8184
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       ace2
      </keyword>
      <keyword majortopicyn="N">
       ards
      </keyword>
      <keyword majortopicyn="N">
       chloroquine
      </keyword>
      <keyword majortopicyn="N">
       covid-19
      </keyword>
      <keyword majortopicyn="N">
       lopinavir and ritonavir
      </keyword>
      <keyword majortopicyn="N">
       mrna-1273 vaccine
      </keyword>
      <keyword majortopicyn="N">
       pandemic
      </keyword>
      <keyword majortopicyn="N">
       remdesivir (gs-5734)
      </keyword>
      <keyword majortopicyn="N">
       sars-cov-2
      </keyword>
      <keyword majortopicyn="N">
       severe acute respiratory infection
      </keyword>
     </keywordlist>
     <coistatement>
      The authors have declared that no competing interests exist.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        1
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32269893
      </articleid>
      <articleid idtype="doi">
       10.7759/cureus.7560
      </articleid>
      <articleid idtype="pmc">
       PMC7138423
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Euro Surveill. 2015 Jun 25;20(25):14-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26132768
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Drug Discov Ther. 2020;14(1):58-60
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32147628
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Mar 4;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32129805
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Res. 2020 Mar;30(3):269-271
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32020029
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Epidemiol. 2004 Sep 15;160(6):509-16
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15353409
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Mar 28;395(10229):1054-1062
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32171076
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2020 Apr;92(4):401-402
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31950516
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nutrients. 2020 Jan 22;12(2):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31978969
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Curr Biol. 2020 Apr 6;30(7):1346-1351.e2
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32197085
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Anesthesiology. 2019 Apr;130(4):581-591
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30676417
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):497-506
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986264
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        BMJ. 2017 Feb 15;356:i6583
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28202713
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2005 Oct 28;310(5748):676-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16195424
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        BMC Med. 2009 Jun 22;7:30
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19545404
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2020 Mar;579(7798):270-273
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32015507
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 26;382(13):1199-1207
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31995857
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Radiology. 2020 Feb 26;:200642
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32101510
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Thorax. 2004 Mar;59(3):252-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14985565
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Mar 7;395(10226):809-815
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32151335
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Hypertension. 2004 May;43(5):970-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15007027
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Hypertens. 2015 Jan;28(1):15-21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24842388
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2020 Apr;20(4):425-434
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32105637
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Viruses. 2019 Oct 24;11(11):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31652964
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 17;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32182409
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Hosp Infect. 2020 Mar;104(3):246-251
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32035997
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2020 Mar 09;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32150618
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Crit Care Med. 2017 Oct;45(10):1683-1695
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28787295
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2005 Nov;5(11):718-25
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16253889
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 18;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32187464
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Sci China Life Sci. 2020 Mar;63(3):457-460
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32009228
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Cell Mol Med. 2015 Aug;19(8):1965-74
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25766467
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS One. 2018 Nov 5;13(11):e0205535
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30395570
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Respir Med. 2020 Apr;8(4):e21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32171062
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Pathog. 2018 Aug 13;14(8):e1007236
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30102747
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Hosp Infect. 2016 Mar;92(3):235-50
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26597631
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):507-513
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32007143
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32250244
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        2050-084X
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         9
        </volume>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          06
         </day>
        </pubdate>
       </journalissue>
       <title>
        eLife
       </title>
       <isoabbreviation>
        Elife
       </isoabbreviation>
      </journal>
      <articletitle>
       Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.7554/eLife.57278
      </elocationid>
      <elocationid eidtype="pii" validyn="Y">
       e57278
      </elocationid>
      <abstract>
       <abstracttext>
        The discovery that SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) binds to the angiotensin converting enzyme (ACE)-2, which is highly expressed in the lower airways, explained why SARS-CoV-2 causes acute respiratory distress syndrome (ARDS) and respiratory failure. After this, news spread that ACEis and ARBs would be harmful in SARS-CoV-2-infected subjects. To the contrary, compelling evidence exists that the ACE-1/angiotensin(Ang)II/ATR-1 pathway is involved in SARS-CoV-2-induced ARDS, while the ACE-2/Ang(1-7)/ATR2/MasR pathway counteracts the harmful actions of AngII in the lung. A reduced ACE-1/ACE-2 ratio is, in fact, a feature of ARDS that can be rescued by human recombinant ACE-2 and Ang(1-7) administration, thus preventing SARS-CoV-2-induced damage to the lung. Based on the current clinical evidence treatment with ACE-inhibitors I (ACEis) or angiotensin receptor blockers (ARBs) continues to provide cardiovascular and renal protection in patients diagnosed with COVID-19. Discontinuing these medications may therefore be potentially harmful in this patient population.
       </abstracttext>
       <copyrightinformation>
        © 2020, Rossi et al.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Rossi
        </lastname>
        <forename>
         Gian Paolo
        </forename>
        <initials>
         GP
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-7963-0931
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Medicine-DIMED - Hypertension Unit, University of Padova, Padova, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Sanga
        </lastname>
        <forename>
         Viola
        </forename>
        <initials>
         V
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medicine-DIMED - Hypertension Unit, University of Padova, Padova, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Barton
        </lastname>
        <forename>
         Matthias
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          University of Zurich, Zurich, Switzerland.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       Elife
      </medlineta>
      <nlmuniqueid>
       101579614
      </nlmuniqueid>
      <issnlinking>
       2050-084X
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       human biology
      </keyword>
      <keyword majortopicyn="N">
       medicine
      </keyword>
     </keywordlist>
     <coistatement>
      GR, VS The other authors declare that no competing interests exist. MB Matthias Barton, Senior Editor, eLife.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        26
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        03
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        7
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        7
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        7
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32250244
      </articleid>
      <articleid idtype="doi">
       10.7554/eLife.57278
      </articleid>
      <articleid idtype="pii">
       57278
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32061198
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       02
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Print">
        1001-0939
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         43
        </volume>
        <issue>
         0
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Feb
         </month>
         <day>
          16
         </day>
        </pubdate>
       </journalissue>
       <title>
        Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
       </title>
       <isoabbreviation>
        Zhonghua Jie He He Hu Xi Za Zhi
       </isoabbreviation>
      </journal>
      <articletitle>
       [Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].
      </articletitle>
      <pagination>
       <medlinepgn>
        E014
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.3760/cma.j.issn.1001-0939.2020.0014
      </elocationid>
      <abstract>
       <abstracttext>
        The novel coronavirus 2019 (COVID-19) infected patients by binding human ACE2, leading to severe pneumonia and highly mortality rate in patients. At present, there is no definite and effective treatment for COVID-19. ACE2 plays an important role in the RAS, and the imbalance between ACE/Ang II/AT1R pathway and ACE2/Ang (1-7)/Mas receptor pathway in the RAS system will lead to multi-system inflammation. Increased ACE and Ang II are poor prognostic factors for severe pneumonia. Animal studies have shown that RAS inhibitors could effectively relieve symptoms of acute severe pneumonia and respiratory failure. The binding of COVID-19 and ACE2 resulted in the exhaustion of ACE2, and then ACE2/Ang (1-7)/Mas receptor pathway was inhibited. The balance of the RAS system was broken, and this would lead to the exacerbation of acute severe pneumonia. Therefore, we speculate that ACEI and AT1R inhibitors could be used in patients with COVID-19 pneumonia under the condition of controlling blood pressure, and might reduce the pulmonary inflammatory response and mortality.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Sun
        </lastname>
        <forename>
         M L
        </forename>
        <initials>
         ML
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         J M
        </forename>
        <initials>
         JM
        </initials>
        <affiliationinfo>
         <affiliation>
          The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese Ministry of Health and Chinese Academy of Medical Sciences, Department of Cardiology, Qilu Hospital of Shandong University, Jinan 250012, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Sun
        </lastname>
        <forename>
         Y P
        </forename>
        <initials>
         YP
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Su
        </lastname>
        <forename>
         G H
        </forename>
        <initials>
         GH
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       chi
      </language>
      <grantlist completeyn="Y">
       <grant>
        <grantid>
         201907031
        </grantid>
        <agency>
         Jinan Science and Technology Development Plan
        </agency>
        <country>
        </country>
       </grant>
       <grant>
        <grantid>
         81570324, 81970366
        </grantid>
        <agency>
         National Natural Science Foundation of China
        </agency>
        <country>
        </country>
       </grant>
      </grantlist>
      <publicationtypelist>
       <publicationtype ui="D004740">
        English Abstract
       </publicationtype>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        16
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       China
      </country>
      <medlineta>
       Zhonghua Jie He He Hu Xi Za Zhi
      </medlineta>
      <nlmuniqueid>
       8712226
      </nlmuniqueid>
      <issnlinking>
       1001-0939
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <otherabstract language="chi" type="Publisher">
      <abstracttext>
       新型冠状病毒通过与人体血管紧张素转化酶2（ACE2）结合感染产生重症肺炎，传染性强，病死率高，目前无确切有效的治疗方式。ACE2是肾素-血管紧张素系统（RAS）的重要组成部分，RAS系统中ACE/Ang II/AT1R通路与ACE2/Ang (1-7)/Mas受体通路失衡将导致多系统炎症。ACE和Ang II升高是重症肺炎的不良预后因素。动物实验结果显示，应用RAS抑制剂可以有效缓解急性重症肺炎症状，缓解呼吸衰竭。新型冠状病毒与ACE2的结合导致ACE2耗竭，ACE2/Ang (1-7)/Mas受体通路受到抑制，RAS系统失衡，使新型冠状病毒肺炎患者病死率升高。因此，在控制血压的情况下，对新型冠状病毒肺炎患者应用ACEI及AT1R抑制剂，有可能减轻患者肺部炎症反应，降低患者病死率。.
      </abstracttext>
     </otherabstract>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        2
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        2
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        2
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32061198
      </articleid>
      <articleid idtype="doi">
       10.3760/cma.j.issn.1001-0939.2020.0014
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32203189
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       03
      </month>
      <day>
       26
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        2042-0226
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Mar
         </month>
         <day>
          19
         </day>
        </pubdate>
       </journalissue>
       <title>
        Cellular &amp; molecular immunology
       </title>
       <isoabbreviation>
        Cell. Mol. Immunol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1038/s41423-020-0400-4
      </elocationid>
      <abstract>
       <abstracttext>
        The outbreak of Coronavirus Disease 2019 (COVID-19) has posed a serious threat to global public health, calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV). The CoV spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Here, we identified the receptor-binding domain (RBD) in SARS-CoV-2 S protein and found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibited significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. SARS-CoV RBD-specific antibodies could cross-react with SARS-CoV-2 RBD protein, and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV RBD-based vaccines for prevention of SARS-CoV-2 and SARS-CoV infection.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Tai
        </lastname>
        <forename>
         Wanbo
        </forename>
        <initials>
         W
        </initials>
        <affiliationinfo>
         <affiliation>
          Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         He
        </lastname>
        <forename>
         Lei
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          Beijing Institute of Microbiology and Epidemiology, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Xiujuan
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Pu
        </lastname>
        <forename>
         Jing
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Voronin
        </lastname>
        <forename>
         Denis
        </forename>
        <initials>
         D
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-2652-0787
        </identifier>
        <affiliationinfo>
         <affiliation>
          Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Jiang
        </lastname>
        <forename>
         Shibo
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA. sjiang@nybc.org.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, China. sjiang@nybc.org.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhou
        </lastname>
        <forename>
         Yusen
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Beijing Institute of Microbiology and Epidemiology, Beijing, China. yszhou@bmi.ac.cn.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Du
        </lastname>
        <forename>
         Lanying
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA. ldu@nybc.org.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <grantlist completeyn="Y">
       <grant>
        <grantid>
         R01 AI137472
        </grantid>
        <acronym>
         AI
        </acronym>
        <agency>
         NIAID NIH HHS
        </agency>
        <country>
         United States
        </country>
       </grant>
       <grant>
        <grantid>
         R01 AI139092
        </grantid>
        <acronym>
         AI
        </acronym>
        <agency>
         NIAID NIH HHS
        </agency>
        <country>
         United States
        </country>
       </grant>
       <grant>
        <grantid>
         R01AI139092
        </grantid>
        <agency>
         U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)
        </agency>
        <country>
        </country>
       </grant>
       <grant>
        <grantid>
         R01AI137472
        </grantid>
        <agency>
         U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)
        </agency>
        <country>
        </country>
       </grant>
      </grantlist>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        19
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       China
      </country>
      <medlineta>
       Cell Mol Immunol
      </medlineta>
      <nlmuniqueid>
       101242872
      </nlmuniqueid>
      <issnlinking>
       1672-7681
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       2019 novel coronavirus
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       cross-neutralization
      </keyword>
      <keyword majortopicyn="N">
       receptor-binding domain
      </keyword>
      <keyword majortopicyn="N">
       spike protein
      </keyword>
      <keyword majortopicyn="N">
       viral inhibitor
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        03
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        06
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        24
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        24
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        24
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32203189
      </articleid>
      <articleid idtype="doi">
       10.1038/s41423-020-0400-4
      </articleid>
      <articleid idtype="pii">
       10.1038/s41423-020-0400-4
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32294179
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1945-7189
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          15
         </day>
        </pubdate>
       </journalissue>
       <title>
        Endocrine reviews
       </title>
       <isoabbreviation>
        Endocr. Rev.
       </isoabbreviation>
      </journal>
      <articletitle>
       Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       bnaa011
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1210/endrev/bnaa011
      </elocationid>
      <abstract>
       <abstracttext>
        Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic and viral infections. The severe acute respiratory syndrome (SARS)-CoV2 (also referred to as COVID-19) coronavirus pandemic highlights the importance of understanding shared disease pathophysiology potentially informing therapeutic choices in individuals with Type 2 diabetes (T2D). Two coronavirus receptor proteins, Angiotensin Converting Enzyme 2 (ACE2) and Dipeptidyl Peptidase-4 (DPP4) are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are known to modify the biological activities of multiple immunomodulatory substrates. Here we review the basic and clinical science spanning the intersections of diabetes, coronavirus infections, ACE2, and DPP4 biology, highlighting clinical relevance and evolving areas of uncertainty underlying the pathophysiology and treatment of T2D in the context of coronavirus infection.
       </abstracttext>
       <copyrightinformation>
        © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Drucker
        </lastname>
        <forename>
         Daniel J
        </forename>
        <initials>
         DJ
        </initials>
        <affiliationinfo>
         <affiliation>
          From the Lunenfeld-Tanenbaum Research Institute, Department of Medicine, Mt. Sinai Hospital, University of Toronto, Toronto Ontario, Canada.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        15
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Endocr Rev
      </medlineta>
      <nlmuniqueid>
       8006258
      </nlmuniqueid>
      <issnlinking>
       0163-769X
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Angiotensin Converting Enzyme 2
      </keyword>
      <keyword majortopicyn="N">
       Diabetes
      </keyword>
      <keyword majortopicyn="N">
       Dipeptidyl Peptidase-4
      </keyword>
      <keyword majortopicyn="N">
       Obesity
      </keyword>
      <keyword majortopicyn="N">
       Receptor
      </keyword>
      <keyword majortopicyn="N">
       Virus
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        07
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32294179
      </articleid>
      <articleid idtype="pii">
       5820492
      </articleid>
      <articleid idtype="doi">
       10.1210/endrev/bnaa011
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32277367
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       11
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1434-9949
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        Clinical rheumatology
       </title>
       <isoabbreviation>
        Clin. Rheumatol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1007/s10067-020-05073-9
      </elocationid>
      <abstract>
       <abstracttext>
        The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren's syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still's disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.Key Points• Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leucopenia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis.• Although preliminary results may be encouraging, high-quality clinical trials are needed to better understand the role of drugs commonly used in rheumatology like hydroxychloroquine and tocilizumab in COVID-19.• Until further evidence emerges, it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Misra
        </lastname>
        <forename>
         Durga Prasanna
        </forename>
        <initials>
         DP
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-5035-7396
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. durgapmisra@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Agarwal
        </lastname>
        <forename>
         Vikas
        </forename>
        <initials>
         V
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-4508-1233
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Gasparyan
        </lastname>
        <forename>
         Armen Yuri
        </forename>
        <initials>
         AY
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0001-8749-6018
        </identifier>
        <affiliationinfo>
         <affiliation>
          Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zimba
        </lastname>
        <forename>
         Olena
        </forename>
        <initials>
         O
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-4188-8486
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Internal Medicine #2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Germany
      </country>
      <medlineta>
       Clin Rheumatol
      </medlineta>
      <nlmuniqueid>
       8211469
      </nlmuniqueid>
      <issnlinking>
       0770-3198
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Epidemiology
      </keyword>
      <keyword majortopicyn="N">
       Hydroxychloroquine
      </keyword>
      <keyword majortopicyn="N">
       Hypothesis
      </keyword>
      <keyword majortopicyn="N">
       Immunity
      </keyword>
      <keyword majortopicyn="N">
       Pathogenesis
      </keyword>
      <keyword majortopicyn="N">
       Vaccines
      </keyword>
      <keyword majortopicyn="N">
       Vitamin D
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        24
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        31
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        29
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32277367
      </articleid>
      <articleid idtype="doi">
       10.1007/s10067-020-05073-9
      </articleid>
      <articleid idtype="pii">
       10.1007/s10067-020-05073-9
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32221306
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       02
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Electronic">
        2041-1723
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         11
        </volume>
        <issue>
         1
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          03
         </month>
         <day>
          27
         </day>
        </pubdate>
       </journalissue>
       <title>
        Nature communications
       </title>
       <isoabbreviation>
        Nat Commun
       </isoabbreviation>
      </journal>
      <articletitle>
       Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.
      </articletitle>
      <pagination>
       <medlinepgn>
        1620
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1038/s41467-020-15562-9
      </elocationid>
      <abstract>
       <abstracttext>
        Since 2002, beta coronaviruses (CoV) have caused three zoonotic outbreaks, SARS-CoV in 2002-2003, MERS-CoV in 2012, and the newly emerged SARS-CoV-2 in late 2019. However, little is currently known about the biology of SARS-CoV-2. Here, using SARS-CoV-2 S protein pseudovirus system, we confirm that human angiotensin converting enzyme 2 (hACE2) is the receptor for SARS-CoV-2, find that SARS-CoV-2 enters 293/hACE2 cells mainly through endocytosis, that PIKfyve, TPC2, and cathepsin L are critical for entry, and that SARS-CoV-2 S protein is less stable than SARS-CoV S. Polyclonal anti-SARS S1 antibodies T62 inhibit entry of SARS-CoV S but not SARS-CoV-2 S pseudovirions. Further studies using recovered SARS and COVID-19 patients' sera show limited cross-neutralization, suggesting that recovery from one infection might not protect against the other. Our results present potential targets for development of drugs and vaccines for SARS-CoV-2.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Ou
        </lastname>
        <forename>
         Xiuyuan
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Yan
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lei
        </lastname>
        <forename>
         Xiaobo
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         Pei
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Mi
        </lastname>
        <forename>
         Dan
        </forename>
        <initials>
         D
        </initials>
        <affiliationinfo>
         <affiliation>
          NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ren
        </lastname>
        <forename>
         Lili
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Guo
        </lastname>
        <forename>
         Li
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Guo
        </lastname>
        <forename>
         Ruixuan
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         Ting
        </forename>
        <initials>
         T
        </initials>
        <affiliationinfo>
         <affiliation>
          NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hu
        </lastname>
        <forename>
         Jiaxin
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xiang
        </lastname>
        <forename>
         Zichun
        </forename>
        <initials>
         Z
        </initials>
        <affiliationinfo>
         <affiliation>
          NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Mu
        </lastname>
        <forename>
         Zhixia
        </forename>
        <initials>
         Z
        </initials>
        <affiliationinfo>
         <affiliation>
          NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         Xing
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Medicinal Plant Development (IMPLAD), Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical Collage (PUMC), 151 Malianwa Road North, Haidian District, 100193, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         Jieyong
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Hengshui Third People's Hospital, Heibei, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hu
        </lastname>
        <forename>
         Keping
        </forename>
        <initials>
         K
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Medicinal Plant Development (IMPLAD), Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical Collage (PUMC), 151 Malianwa Road North, Haidian District, 100193, Beijing, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Jin
        </lastname>
        <forename>
         Qi
        </forename>
        <initials>
         Q
        </initials>
        <affiliationinfo>
         <affiliation>
          NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China. jinqi@ipbcams.ac.cn.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Jianwei
        </forename>
        <initials>
         J
        </initials>
        <identifier source="ORCID">
         0000-0002-1116-4559
        </identifier>
        <affiliationinfo>
         <affiliation>
          NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China. wangjw28@163.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Qian
        </lastname>
        <forename>
         Zhaohui
        </forename>
        <initials>
         Z
        </initials>
        <identifier source="ORCID">
         0000-0003-4116-4450
        </identifier>
        <affiliationinfo>
         <affiliation>
          NHC Key laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 100176, Beijing, China. zqian2013@sina.com.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <grantlist completeyn="Y">
       <grant>
        <grantid>
         31970171
        </grantid>
        <agency>
         National Natural Science Foundation of China (National Science Foundation of China)
        </agency>
        <country>
         International
        </country>
       </grant>
       <grant>
        <grantid>
         31670164
        </grantid>
        <agency>
         National Natural Science Foundation of China (National Science Foundation of China)
        </agency>
        <country>
         International
        </country>
       </grant>
      </grantlist>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D013485">
        Research Support, Non-U.S. Gov't
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        27
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       Nat Commun
      </medlineta>
      <nlmuniqueid>
       101528555
      </nlmuniqueid>
      <issnlinking>
       2041-1723
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000914">
        Antibodies, Viral
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000080908">
        Broadly Neutralizing Antibodies
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D015220">
        Calcium Channels
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D011991">
        Receptors, Virus
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D064370">
        Spike Glycoprotein, Coronavirus
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C530224">
        TPCN2 protein, human
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C000657845">
        spike glycoprotein, COVID-19 virus
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C578557">
        spike glycoprotein, SARS-CoV
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 2.7.1.137
       </registrynumber>
       <nameofsubstance ui="C492139">
        PIKFYVE protein, human
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.-
       </registrynumber>
       <nameofsubstance ui="D002403">
        Cathepsins
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.15.1
       </registrynumber>
       <nameofsubstance ui="D007703">
        Peptidyl-Dipeptidase A
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.17.-
       </registrynumber>
       <nameofsubstance ui="C413524">
        angiotensin converting enzyme 2
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.21.4
       </registrynumber>
       <nameofsubstance ui="D014357">
        Trypsin
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.22.15
       </registrynumber>
       <nameofsubstance ui="D056668">
        Cathepsin L
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000914">
        Antibodies, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000276">
        immunology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000737">
        chemistry
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000276">
        immunology
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000502">
        physiology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000080908">
        Broadly Neutralizing Antibodies
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000276">
        immunology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D015220">
        Calcium Channels
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D056668">
        Cathepsin L
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002403">
        Cathepsins
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000037">
        antagonists &amp; inhibitors
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002459">
        Cell Fusion
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000276">
        immunology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D003429">
        Cross Reactions
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D004705">
        Endocytosis
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D015726">
        Giant Cells
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000502">
        physiology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D057809">
        HEK293 Cells
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D009500">
        Neutralization Tests
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007703">
        Peptidyl-Dipeptidase A
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D019869">
        Phosphatidylinositol 3-Kinases
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000276">
        immunology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000072417">
        Protein Domains
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D055503">
        Protein Multimerization
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011991">
        Receptors, Virus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D045473">
        SARS Virus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000276">
        immunology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D045169">
        Severe Acute Respiratory Syndrome
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000276">
        immunology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D064370">
        Spike Glycoprotein, Coronavirus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000737">
        chemistry
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000276">
        immunology
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D014357">
        Trypsin
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D053586">
        Virus Internalization
       </descriptorname>
      </meshheading>
     </meshheadinglist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        13
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        16
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        30
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        30
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        3
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32221306
      </articleid>
      <articleid idtype="doi">
       10.1038/s41467-020-15562-9
      </articleid>
      <articleid idtype="pii">
       10.1038/s41467-020-15562-9
      </articleid>
      <articleid idtype="pmc">
       PMC7100515
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2003 May 15;348(20):1953-66
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12690092
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2016 May 27;90(12):5586-5600
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27030273
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Cell Sci. 2006 Oct 1;119(Pt 19):3944-57
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16954148
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2681-2690
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30679277
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26976607
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2015 Feb 27;347(6225):995-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25722412
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Host Microbe. 2017 Mar 8;21(3):367-375
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28238624
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2011 Dec;85(24):13363-72
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21994442
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2013 May;87(10):5502-11
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23468491
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Traffic. 2009 Jul;10(7):883-93
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19582903
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2020 Mar;579(7798):270-273
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32015507
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Struct Mol Biol. 2019 Dec;26(12):1151-1157
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31792450
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Calcium. 2018 Nov;75:30-41
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30121440
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2015 Jul;89(14):7202-13
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25926653
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Epidemiol Infect. 2007 Nov;135(8):1231-47
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17445320
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2003 Oct 10;302(5643):276-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12958366
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Feb 20;382(8):727-733
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31978945
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2013 Aug 8;500(7461):227-31
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23831647
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2018 May 14;92(11):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29514915
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell. 2016 Nov 3;167(4):1079-1087.e5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27814505
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell. 2016 Nov 3;167(4):1088-1098.e6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27814506
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2012 Nov 8;367(19):1814-20
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23075143
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2003 Nov 27;426(6965):450-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14647384
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trends Biochem Sci. 2019 Feb;44(2):110-124
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30424907
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2015 Feb;89(4):1954-64
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25428871
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2003 May 15;348(20):1967-76
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12690091
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5533-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         1648219
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2013 Jun;87(11):6150-60
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23536651
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5871-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19321428
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2013 Mar 14;495(7440):251-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23486063
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2008 Sep;82(17):8942-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18562527
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16081529
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 1994 Sep;68(9):5403-10
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         7520090
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2011 May;85(9):4122-34
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21325420
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Chin Med J (Engl). 2020 Feb 11;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32004165
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2010 Dec;84(24):12658-64
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20926566
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2013 Dec;87(23):12552-61
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24027332
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Res. 2013 Aug;23(8):986-93
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23835475
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell. 2020 Mar 4;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32142651
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):497-506
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986264
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2005 Sep 16;309(5742):1864-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16166518
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Commun. 2017 May 23;8:15216
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28534504
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS One. 2013 Oct 03;8(10):e76469
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24098509
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2015 Sep;89(17):8816-27
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26085157
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15214-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25288733
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12262-12267
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27791014
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Negl Trop Dis. 2017 Apr 12;11(4):e0005540
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28403145
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2005 Oct 28;310(5748):676-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16195424
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32233753
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       07
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       08
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        2047-9980
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         9
        </volume>
        <issue>
         7
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          04
         </month>
         <day>
          07
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of the American Heart Association
       </title>
       <isoabbreviation>
        J Am Heart Assoc
       </isoabbreviation>
      </journal>
      <articletitle>
       Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
      </articletitle>
      <pagination>
       <medlinepgn>
        e016509
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1161/JAHA.120.016509
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Sommerstein
        </lastname>
        <forename>
         Rami
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Infectious Diseases Bern University Hospital Bern Switzerland.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kochen
        </lastname>
        <forename>
         Michael M
        </forename>
        <initials>
         MM
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Family Medicine University of Freiburg Germany.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Messerli
        </lastname>
        <forename>
         Franz H
        </forename>
        <initials>
         FH
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology Bern University Hospital Bern Switzerland.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Jagiellonian University Krakow Poland.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Division of Cardiology Mount Sinai Health Medical Center Icahn School of Medicine New York NY.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Gräni
        </lastname>
        <forename>
         Christoph
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology Bern University Hospital Bern Switzerland.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        01
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       J Am Heart Assoc
      </medlineta>
      <nlmuniqueid>
       101580524
      </nlmuniqueid>
      <issnlinking>
       2047-9980
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D057911">
        Angiotensin Receptor Antagonists
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.15.1
       </registrynumber>
       <nameofsubstance ui="D007703">
        Peptidyl-Dipeptidase A
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.17.-
       </registrynumber>
       <nameofsubstance ui="C413524">
        angiotensin converting enzyme 2
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <commentscorrectionslist>
      <commentscorrections reftype="CommentIn">
       <refsource>
        J Am Heart Assoc. 2020 Apr 7;9(7):e016219
       </refsource>
       <pmid version="1">
        32233755
       </pmid>
      </commentscorrections>
     </commentscorrectionslist>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D057911">
        Angiotensin Receptor Antagonists
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000009">
        adverse effects
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000494">
        pharmacology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000009">
        adverse effects
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000494">
        pharmacology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000187">
        drug effects
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D002318">
        Cardiovascular Diseases
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000150">
        complications
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D015897">
        Comorbidity
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000150">
        complications
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000401">
        mortality
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018563">
        Disease Notification
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007703">
        Peptidyl-Dipeptidase A
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000187">
        drug effects
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000150">
        complications
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000401">
        mortality
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D012307">
        Risk Factors
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D012720">
        Severity of Illness Index
       </descriptorname>
      </meshheading>
     </meshheadinglist>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="Y">
       ACE2
      </keyword>
      <keyword majortopicyn="Y">
       angiotensin II receptor blocker
      </keyword>
      <keyword majortopicyn="Y">
       angiotensin‐converting enzyme inhibitor
      </keyword>
      <keyword majortopicyn="Y">
       coronavirus disease 2019
      </keyword>
      <keyword majortopicyn="Y">
       epidemiology
      </keyword>
      <keyword majortopicyn="Y">
       infectious diseases
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        3
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        3
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        9
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32233753
      </articleid>
      <articleid idtype="doi">
       10.1161/JAHA.120.016509
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32228252
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1522-1539
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         318
        </volume>
        <issue>
         5
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          05
         </month>
         <day>
          01
         </day>
        </pubdate>
       </journalissue>
       <title>
        American journal of physiology. Heart and circulatory physiology
       </title>
       <isoabbreviation>
        Am. J. Physiol. Heart Circ. Physiol.
       </isoabbreviation>
      </journal>
      <articletitle>
       COVID-19, ACE2, and the cardiovascular consequences.
      </articletitle>
      <pagination>
       <medlinepgn>
        H1084-H1090
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1152/ajpheart.00217.2020
      </elocationid>
      <abstract>
       <abstracttext>
        The novel SARS coronavirus SARS-CoV-2 pandemic may be particularly deleterious to patients with underlying cardiovascular disease (CVD). The mechanism for SARS-CoV-2 infection is the requisite binding of the virus to the membrane-bound form of angiotensin-converting enzyme 2 (ACE2) and internalization of the complex by the host cell. Recognition that ACE2 is the coreceptor for the coronavirus has prompted new therapeutic approaches to block the enzyme or reduce its expression to prevent the cellular entry and SARS-CoV-2 infection in tissues that express ACE2 including lung, heart, kidney, brain, and gut. ACE2, however, is a key enzymatic component of the renin-angiotensin-aldosterone system (RAAS); ACE2 degrades ANG II, a peptide with multiple actions that promote CVD, and generates Ang-(1-7), which antagonizes the effects of ANG II. Moreover, experimental evidence suggests that RAAS blockade by ACE inhibitors, ANG II type 1 receptor antagonists, and mineralocorticoid antagonists, as well as statins, enhance ACE2 which, in part, contributes to the benefit of these regimens. In lieu of the fact that many older patients with hypertension or other CVDs are routinely treated with RAAS blockers and statins, new clinical concerns have developed regarding whether these patients are at greater risk for SARS-CoV-2 infection, whether RAAS and statin therapy should be discontinued, and the potential consequences of RAAS blockade to COVID-19-related pathologies such as acute and chronic respiratory disease. The current perspective critically examines the evidence for ACE2 regulation by RAAS blockade and statins, the cardiovascular benefits of ACE2, and whether ACE2 blockade is a viable approach to attenuate COVID-19.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         South
        </lastname>
        <forename>
         Andrew M
        </forename>
        <initials>
         AM
        </initials>
        <identifier source="ORCID">
         0000-0002-3204-4142
        </identifier>
        <affiliationinfo>
         <affiliation>
          Cardiovascular Sciences Center, Wake Forest School of Medicine, Winston-Salem, North Carolina.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Diz
        </lastname>
        <forename>
         Debra I
        </forename>
        <initials>
         DI
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiovascular Sciences Center, Wake Forest School of Medicine, Winston-Salem, North Carolina.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chappell
        </lastname>
        <forename>
         Mark C
        </forename>
        <initials>
         MC
        </initials>
        <identifier source="ORCID">
         0000-0001-5869-6037
        </identifier>
        <affiliationinfo>
         <affiliation>
          Cardiovascular Sciences Center, Wake Forest School of Medicine, Winston-Salem, North Carolina.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <grantlist completeyn="Y">
       <grant>
        <grantid>
         R01 HL146818
        </grantid>
        <acronym>
         HL
        </acronym>
        <agency>
         NHLBI NIH HHS
        </agency>
        <country>
         United States
        </country>
       </grant>
       <grant>
        <grantid>
         R21 HD084227
        </grantid>
        <acronym>
         HD
        </acronym>
        <agency>
         NICHD NIH HHS
        </agency>
        <country>
         United States
        </country>
       </grant>
      </grantlist>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D052061">
        Research Support, N.I.H., Extramural
       </publicationtype>
       <publicationtype ui="D013485">
        Research Support, Non-U.S. Gov't
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        31
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Am J Physiol Heart Circ Physiol
      </medlineta>
      <nlmuniqueid>
       100901228
      </nlmuniqueid>
      <issnlinking>
       0363-6135
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        EC 3.4.15.1
       </registrynumber>
       <nameofsubstance ui="D007703">
        Peptidyl-Dipeptidase A
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.17.-
       </registrynumber>
       <nameofsubstance ui="C413524">
        angiotensin converting enzyme 2
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000818">
        Animals
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000502">
        physiology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002318">
        Cardiovascular Diseases
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000201">
        enzymology
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000201">
        enzymology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D008297">
        Male
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007703">
        Peptidyl-Dipeptidase A
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000201">
        enzymology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D051381">
        Rats
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011917">
        Rats, Inbred Lew
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D053586">
        Virus Internalization
       </descriptorname>
      </meshheading>
     </meshheadinglist>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="Y">
       ACE2
      </keyword>
      <keyword majortopicyn="Y">
       ANG II
      </keyword>
      <keyword majortopicyn="Y">
       COVID-19
      </keyword>
      <keyword majortopicyn="Y">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="Y">
       renin-angiotensin system
      </keyword>
      <keyword majortopicyn="Y">
       statins
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        2
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        2
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32228252
      </articleid>
      <articleid idtype="doi">
       10.1152/ajpheart.00217.2020
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation indexingmethod="Curated" owner="NLM" status="MEDLINE">
     <pmid version="1">
      32164092
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       03
      </month>
      <day>
       20
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print">
      <journal>
       <issn issntype="Print">
        1001-0939
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         43
        </volume>
        <issue>
         3
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Mar
         </month>
         <day>
          12
         </day>
        </pubdate>
       </journalissue>
       <title>
        Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
       </title>
       <isoabbreviation>
        Zhonghua Jie He He Hu Xi Za Zhi
       </isoabbreviation>
      </journal>
      <articletitle>
       [Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].
      </articletitle>
      <pagination>
       <medlinepgn>
        219-222
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.3760/cma.j.issn.1001-0939.2020.03.016
      </elocationid>
      <abstract>
       <abstracttext>
        The novel coronavirus 2019 (COVID-19) infected patients by binding human ACE2, leading to severe pneumonia and highly mortality rate in patients. At present, there is no definite and effective treatment for COVID-19. ACE2 plays an important role in the RAS, and the imbalance between ACE/Ang II/AT1R pathway and ACE2/Ang (1-7)/Mas receptor pathway in the RAS system will lead to multi-system inflammation. Increased ACE and Ang II are poor prognostic factors for severe pneumonia. Animal studies have shown that RAS inhibitors could effectively relieve symptoms of acute severe pneumonia and respiratory failure. The binding of COVID-19 and ACE2 resulted in the exhaustion of ACE2, and then ACE2/Ang (1-7)/Mas receptor pathway was inhibited. The balance of the RAS system was broken, and this would lead to the exacerbation of acute severe pneumonia. Therefore, we speculate that ACEI and AT1R inhibitors could be used in patients with COVID-19 pneumonia under the condition of controlling blood pressure, and might reduce the pulmonary inflammatory response and mortality.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Sun
        </lastname>
        <forename>
         M L
        </forename>
        <initials>
         ML
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         J M
        </forename>
        <initials>
         JM
        </initials>
        <affiliationinfo>
         <affiliation>
          The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese Ministry of Health and Chinese Academy of Medical Sciences, Department of Cardiology, Qilu Hospital of Shandong University, Jinan 250012, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Sun
        </lastname>
        <forename>
         Y P
        </forename>
        <initials>
         YP
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Su
        </lastname>
        <forename>
         G H
        </forename>
        <initials>
         GH
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       chi
      </language>
      <grantlist completeyn="Y">
       <grant>
        <grantid>
         201907031
        </grantid>
        <agency>
         Jinan Science and Technology Development Plan
        </agency>
        <country>
        </country>
       </grant>
       <grant>
        <grantid>
         81570324, 81970366
        </grantid>
        <agency>
         National Natural Science Foundation of China
        </agency>
        <country>
        </country>
       </grant>
      </grantlist>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
     </article>
     <medlinejournalinfo>
      <country>
       China
      </country>
      <medlineta>
       Zhonghua Jie He He Hu Xi Za Zhi
      </medlineta>
      <nlmuniqueid>
       8712226
      </nlmuniqueid>
      <issnlinking>
       1001-0939
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D010446">
        Peptide Fragments
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        11128-99-7
       </registrynumber>
       <nameofsubstance ui="D000804">
        Angiotensin II
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.15.1
       </registrynumber>
       <nameofsubstance ui="C488034">
        ACE protein, human
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.15.1
       </registrynumber>
       <nameofsubstance ui="D007703">
        Peptidyl-Dipeptidase A
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.17.-
       </registrynumber>
       <nameofsubstance ui="C413524">
        angiotensin converting enzyme 2
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000804">
        Angiotensin II
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000818">
        Animals
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D000073640">
        Betacoronavirus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000187">
        drug effects
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000472">
        pathogenicity
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D001794">
        Blood Pressure
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000187">
        drug effects
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D007249">
        Inflammation
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000209">
        etiology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D008168">
        Lung
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D010446">
        Peptide Fragments
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D007703">
        Peptidyl-Dipeptidase A
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000187">
        drug effects
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000502">
        physiology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000209">
        etiology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011379">
        Prognosis
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D012084">
        Renin-Angiotensin System
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000187">
        drug effects
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000502">
        physiology
       </qualifiername>
      </meshheading>
     </meshheadinglist>
     <otherabstract language="chi" type="Publisher">
      <abstracttext>
       新型冠状病毒通过与人体血管紧张素转化酶2（ACE2）结合感染产生重症肺炎，传染性强，病死率高，目前无确切有效的治疗方式。ACE2是肾素-血管紧张素系统（RAS）的重要组成部分，RAS系统中ACE/Ang II/AT1R通路与ACE2/Ang(1-7)/Mas受体通路失衡将导致多系统炎症。ACE和Ang II升高是重症肺炎的不良预后因素。动物实验结果显示，应用RAS抑制剂可以有效缓解急性重症肺炎症状，缓解呼吸衰竭。新型冠状病毒与ACE2的结合导致ACE2耗竭，ACE2/Ang (1-7)/Mas受体通路受到抑制，RAS系统失衡，使新型冠状病毒肺炎患者病死率升高。因此，在控制血压的情况下，对新型冠状病毒肺炎患者应用ACEI及AT1R抑制剂，有可能减轻患者肺部炎症反应，降低患者病死率。.
      </abstracttext>
     </otherabstract>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        13
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        21
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32164092
      </articleid>
      <articleid idtype="doi">
       10.3760/cma.j.issn.1001-0939.2020.03.016
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      16054014
     </pmid>
     <datecompleted>
      <year>
       2005
      </year>
      <month>
       09
      </month>
      <day>
       27
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       02
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Print">
        0006-3002
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         1751
        </volume>
        <issue>
         1
        </issue>
        <pubdate>
         <year>
          2005
         </year>
         <month>
          Aug
         </month>
         <day>
          01
         </day>
        </pubdate>
       </journalissue>
       <title>
        Biochimica et biophysica acta
       </title>
       <isoabbreviation>
        Biochim. Biophys. Acta
       </isoabbreviation>
      </journal>
      <articletitle>
       Membrane-associated zinc peptidase families: comparing ACE and ACE2.
      </articletitle>
      <pagination>
       <medlinepgn>
        2-8
       </medlinepgn>
      </pagination>
      <abstract>
       <abstracttext>
        In contrast to the relatively ubiquitous angiotensin-converting enzyme (ACE), expression of the mammalian ACE homologue, ACE2, was initially described in the heart, kidney and testis. ACE2 is a type I integral membrane protein with its active site domain exposed to the extracellular surface of endothelial cells and the renal tubular epithelium. Here ACE2 is poised to metabolise circulating peptides which may include angiotensin II, a potent vasoconstrictor and the product of angiotensin I cleavage by ACE. To this end, ACE2 may counterbalance the effects of ACE within the renin-angiotensin system (RAS). Indeed, ACE2 has been implicated in the regulation of heart and renal function where it is proposed to control the levels of angiotensin II relative to its hypotensive metabolite, angiotensin-(1-7). The recent solution of the structure of ACE2, and ACE, has provided new insight into the substrate and inhibitor profiles of these two key regulators of the RAS. As the complexity of this crucial pathway is unravelled, there is a growing interest in the therapeutic potential of agents that modulate the activity of ACE2.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Guy
        </lastname>
        <forename>
         J L
        </forename>
        <initials>
         JL
        </initials>
        <affiliationinfo>
         <affiliation>
          Proteolysis Research Group, School of Biochemistry and Microbiology, University of Leeds, Leeds, LS2 9JT, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lambert
        </lastname>
        <forename>
         D W
        </forename>
        <initials>
         DW
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Warner
        </lastname>
        <forename>
         F J
        </forename>
        <initials>
         FJ
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Hooper
        </lastname>
        <forename>
         N M
        </forename>
        <initials>
         NM
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Turner
        </lastname>
        <forename>
         A J
        </forename>
        <initials>
         AJ
        </initials>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <grantlist completeyn="Y">
       <grant>
        <acronym>
         WT_
        </acronym>
        <agency>
         Wellcome Trust
        </agency>
        <country>
         United Kingdom
        </country>
       </grant>
      </grantlist>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D013485">
        Research Support, Non-U.S. Gov't
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2004
       </year>
       <month>
        11
       </month>
       <day>
        06
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Biochim Biophys Acta
      </medlineta>
      <nlmuniqueid>
       0217513
      </nlmuniqueid>
      <issnlinking>
       0006-3002
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D029721">
        Drosophila Proteins
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D008562">
        Membrane Glycoproteins
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D011991">
        Receptors, Virus
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.-
       </registrynumber>
       <nameofsubstance ui="D002268">
        Carboxypeptidases
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.15.-
       </registrynumber>
       <nameofsubstance ui="C104431">
        Ance protein, Drosophila
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.15.1
       </registrynumber>
       <nameofsubstance ui="D007703">
        Peptidyl-Dipeptidase A
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.17.-
       </registrynumber>
       <nameofsubstance ui="C413524">
        angiotensin converting enzyme 2
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.24.-
       </registrynumber>
       <nameofsubstance ui="D008666">
        Metalloendopeptidases
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000595">
        Amino Acid Sequence
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000494">
        pharmacology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000818">
        Animals
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D001665">
        Binding Sites
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002268">
        Carboxypeptidases
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D029721">
        Drosophila Proteins
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D008562">
        Membrane Glycoproteins
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D008666">
        Metalloendopeptidases
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007703">
        Peptidyl-Dipeptidase A
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011991">
        Receptors, Virus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D012084">
        Renin-Angiotensin System
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000502">
        physiology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D045473">
        SARS Virus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D013379">
        Substrate Specificity
       </descriptorname>
      </meshheading>
     </meshheadinglist>
     <numberofreferences>
      38
     </numberofreferences>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2004
       </year>
       <month>
        05
       </month>
       <day>
        25
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2004
       </year>
       <month>
        10
       </month>
       <day>
        14
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2004
       </year>
       <month>
        10
       </month>
       <day>
        26
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2005
       </year>
       <month>
        8
       </month>
       <day>
        2
       </day>
       <hour>
        9
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2005
       </year>
       <month>
        9
       </month>
       <day>
        28
       </day>
       <hour>
        9
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2005
       </year>
       <month>
        8
       </month>
       <day>
        2
       </day>
       <hour>
        9
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       16054014
      </articleid>
      <articleid idtype="pii">
       S1570-9639(04)00292-4
      </articleid>
      <articleid idtype="doi">
       10.1016/j.bbapap.2004.10.010
      </articleid>
      <articleid idtype="pmc">
       PMC7105243
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Hypertension. 2004 May;43(5):1120-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15078862
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Eur J Biochem. 1998 Nov 1;257(3):599-606
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         9839949
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        FEBS Lett. 2002 Dec 4;532(1-2):107-10
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12459472
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2001 May 18;276(20):17132-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         11278314
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2003 Nov 27;426(6965):450-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14647384
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2001 Sep 7;276(36):33518-25
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         11432860
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Diabet Med. 2003 Aug;20(8):607-21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12873287
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Cardiovasc Pharmacol. 1987;10 Suppl 7:S1-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         2485038
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Pathol. 2004 Jun;203(2):631-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15141377
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Circ Res. 2000 Sep 1;87(5):E1-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         10969042
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Mol Cell Cardiol. 2003 Sep;35(9):1043-53
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12967627
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Exp Med. 1956 Mar 1;103(3):295-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         13295487
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2004 Apr 23;279(17):17996-8007
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14754895
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        FEBS Lett. 2003 Mar 13;538(1-3):65-70
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12633854
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Circulation. 2003 Oct 7;108(14):1707-12
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14504186
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biochem J. 2003 Apr 15;371(Pt 2):437-42
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12542396
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Endocrinology. 2003 Aug;144(8):3338-43
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12865311
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biochem J. 1996 Aug 15;318 ( Pt 1):125-31
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         8761461
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Endocrinology. 2004 Oct;145(10):4703-11
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15231706
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2002 Jun 20;417(6891):822-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12075344
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Physiol Renal Physiol. 2005 Feb;288(2):F353-62
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15467007
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Hypertension. 2003 Mar;41(3):392-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12623933
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2002 Apr 26;277(17):14838-43
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         11815627
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trends Pharmacol Sci. 2002 Apr;23(4):177-83
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         11931993
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        DNA Seq. 2002 Aug;13(4):217-20
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12487024
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Circulation. 2003 Oct 7;108(14):1679-81
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14504185
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2000 Oct 27;275(43):33238-43
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         10924499
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biochemistry. 2003 Nov 18;42(45):13185-92
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14609329
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2003 May 2;278(18):15532-40
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12606557
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 1980 Jan 25;255(2):401-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         6243277
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2003 Jan 30;421(6922):551-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12540854
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biochim Biophys Acta. 1970 Aug 21;214(2):374-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         4322742
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Hypertension. 2003 Oct;42(4):749-53
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12874086
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Am Chem Soc. 2002 Oct 9;124(40):11852-3
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12358520
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32228222
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       02
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       08
      </day>
     </daterevised>
     <article pubmodel="Print">
      <journal>
       <issn issntype="Electronic">
        2222-1751
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         9
        </volume>
        <issue>
         1
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Dec
         </month>
        </pubdate>
       </journalissue>
       <title>
        Emerging microbes &amp; infections
       </title>
       <isoabbreviation>
        Emerg Microbes Infect
       </isoabbreviation>
      </journal>
      <articletitle>
       Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.
      </articletitle>
      <pagination>
       <medlinepgn>
        757-760
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1080/22221751.2020.1746200
      </elocationid>
      <abstract>
       <abstracttext>
        The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Meng
        </lastname>
        <forename>
         Juan
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, People's Republic of China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Shenzhen Bay Laboratory, Shenzhen, People's Republic of China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xiao
        </lastname>
        <forename>
         Guohui
        </forename>
        <initials>
         G
        </initials>
        <affiliationinfo>
         <affiliation>
          National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, People's Republic of China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Shenzhen Bay Laboratory, Shenzhen, People's Republic of China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Juanjuan
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, People's Republic of China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         He
        </lastname>
        <forename>
         Xing
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, People's Republic of China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ou
        </lastname>
        <forename>
         Min
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, People's Republic of China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bi
        </lastname>
        <forename>
         Jing
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, People's Republic of China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         Rongqing
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, People's Republic of China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Di
        </lastname>
        <forename>
         Wencheng
        </forename>
        <initials>
         W
        </initials>
        <affiliationinfo>
         <affiliation>
          National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, People's Republic of China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Zhaoqin
        </forename>
        <initials>
         Z
        </initials>
        <affiliationinfo>
         <affiliation>
          National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, People's Republic of China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         Zigang
        </forename>
        <initials>
         Z
        </initials>
        <affiliationinfo>
         <affiliation>
          Shenzhen Bay Laboratory, Shenzhen, People's Republic of China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Gao
        </lastname>
        <forename>
         Hong
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, People's Republic of China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Lei
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, People's Republic of China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Guoliang
        </forename>
        <initials>
         G
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-3617-5449
        </identifier>
        <affiliationinfo>
         <affiliation>
          National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, People's Republic of China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Shenzhen Bay Laboratory, Shenzhen, People's Republic of China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Lead Contact.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016422">
        Letter
       </publicationtype>
      </publicationtypelist>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Emerg Microbes Infect
      </medlineta>
      <nlmuniqueid>
       101594885
      </nlmuniqueid>
      <issnlinking>
       2222-1751
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D047228">
        Angiotensin II Type 1 Receptor Blockers
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000959">
        Antihypertensive Agents
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D017252">
        CD3 Complex
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C508600">
        IL6 protein, human
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D015850">
        Interleukin-6
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        9007-41-4
       </registrynumber>
       <nameofsubstance ui="D002097">
        C-Reactive Protein
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000368">
        Aged
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D047228">
        Angiotensin II Type 1 Receptor Blockers
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000959">
        Antihypertensive Agents
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002097">
        C-Reactive Protein
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000032">
        analysis
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D017252">
        CD3 Complex
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018414">
        CD8-Positive T-Lymphocytes
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000166">
        cytology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" type="Geographic" ui="D002681">
        China
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000150">
        complications
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D005260">
        Female
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006973">
        Hypertension
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000150">
        complications
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D015850">
        Interleukin-6
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000097">
        blood
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D008297">
        Male
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D008875">
        Middle Aged
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000150">
        complications
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D012084">
        Renin-Angiotensin System
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D012189">
        Retrospective Studies
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D016896">
        Treatment Outcome
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D019562">
        Viral Load
       </descriptorname>
      </meshheading>
     </meshheadinglist>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Renin-angiotensin system
      </keyword>
      <keyword majortopicyn="N">
       angiotensin II type1 receptor blockers
      </keyword>
      <keyword majortopicyn="N">
       angiotensin-converting enzyme inhibitors
      </keyword>
      <keyword majortopicyn="N">
       hypertension
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        2
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        2
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        3
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32228222
      </articleid>
      <articleid idtype="doi">
       10.1080/22221751.2020.1746200
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32247213
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       19
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1878-0334
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         14
        </volume>
        <issue>
         3
        </issue>
        <pubdate>
         <medlinedate>
          2020 May - Jun
         </medlinedate>
        </pubdate>
       </journalissue>
       <title>
        Diabetes &amp; metabolic syndrome
       </title>
       <isoabbreviation>
        Diabetes Metab Syndr
       </isoabbreviation>
      </journal>
      <articletitle>
       Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc).
      </articletitle>
      <pagination>
       <medlinepgn>
        251-254
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S1871-4021(20)30052-7
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.dsx.2020.03.012
      </elocationid>
      <abstract>
       <abstracttext label="BACKGROUND AND AIMS" nlmcategory="OBJECTIVE">
        Multiple issues in management of COVID have emerged, but confusion persists regarding rational interpretation. Aim of this brief review is to review these issues based on current literature.
       </abstracttext>
       <abstracttext label="METHODS" nlmcategory="METHODS">
        This is a narrative review with Pubmed and Google Scholar search till 23 March 2020. Search terms were, COVID-19, treatment of coronavirus, COVID 19 and following terms; chloroquine, hydroxychloroquine, ibuprofen, ACE-inhibitors or angiotensin receptor blockers, cardiovascular disease, diarrhoea, liver, testis and gastrointestinal disease.
       </abstracttext>
       <abstracttext label="RESULTS" nlmcategory="RESULTS">
        We discuss evidence regarding role of chloroquine and hydroxychloroquine in treatment and prophylaxis, use of inhibitors of the renin angiotensin system, safety of ibuprofen, unusual clinical features like gastrointestinal symptoms and interpretation of tests for cardiac enzymes and biomarkers.
       </abstracttext>
       <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
        While our conclusions on management of COVID-19 patients with co-morbidities are based on current evidence, however, data is limited and there is immediate need for fast track research.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Gupta
        </lastname>
        <forename>
         Ritesh
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Fortis CDOC Hospital, Chirag Enclave, New Delhi, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Misra
        </lastname>
        <forename>
         Anoop
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Fortis CDOC Hospital, Chirag Enclave, New Delhi, India; National Diabetes, Obesity and Cholesterol Foundation, New Delhi, India; Diabetes Foundation (India), New Delhi, India. Electronic address: anoopmisra@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        25
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Diabetes Metab Syndr
      </medlineta>
      <nlmuniqueid>
       101462250
      </nlmuniqueid>
      <issnlinking>
       1871-4021
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        5
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        5
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        5
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32247213
      </articleid>
      <articleid idtype="pii">
       S1871-4021(20)30052-7
      </articleid>
      <articleid idtype="doi">
       10.1016/j.dsx.2020.03.012
      </articleid>
      <articleid idtype="pmc">
       PMC7102586
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32255507
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       07
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1532-5415
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          07
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of the American Geriatrics Society
       </title>
       <isoabbreviation>
        J Am Geriatr Soc
       </isoabbreviation>
      </journal>
      <articletitle>
       COVID-19 And Older Adults: What We Know.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1111/jgs.16472
      </elocationid>
      <abstract>
       <abstracttext>
        SARS-CoV-2, a novel virus that causes COVID-19 infection, has recently emerged and caused a deadly pandemic. Studies have shown that this virus causes worse outcomes and a higher mortality rate in older adults and those with comorbidities such as hypertension, cardiovascular disease, diabetes, chronic respiratory disease, and chronic kidney disease. A significant percentage of older American adults have these diseases, putting them at a higher risk of infection. Additionally, many adults with hypertension, diabetes, and chronic kidney disease are placed on angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). Studies have shown that these medications upregulate the ACE-2 receptor, the very receptor which the SARS-CoV-2 virus uses to enter host cells, which puts older adults at a further increased risk of infection. In this review, we discuss the transmission, symptomatology, mortality, and possible treatments for this infection, as they relate to older adults. This article is protected by copyright. All rights reserved.
       </abstracttext>
       <copyrightinformation>
        This article is protected by copyright. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Shahid
        </lastname>
        <forename>
         Zainab
        </forename>
        <initials>
         Z
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-0716-8338
        </identifier>
        <affiliationinfo>
         <affiliation>
          Lake Erie College of Osteopathic Medicine.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Internal Medicine, Rowan University SOM.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kalayanamitra
        </lastname>
        <forename>
         Ricci
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Penn State College of Medicine.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Emergency Medicine, Staten Island University Hospital, Zucker School of Medicine at Hofstra/Northwell.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         McClafferty
        </lastname>
        <forename>
         Brendan
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Lake Erie College of Osteopathic Medicine.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kepko
        </lastname>
        <forename>
         Douglas
        </forename>
        <initials>
         D
        </initials>
        <affiliationinfo>
         <affiliation>
          Lake Erie College of Osteopathic Medicine.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ramgobin
        </lastname>
        <forename>
         Devyani
        </forename>
        <initials>
         D
        </initials>
        <affiliationinfo>
         <affiliation>
          Touro College of Osteopathic Medicine.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Patel
        </lastname>
        <forename>
         Ravi
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Internal Medicine, Penn State Health Milton S. Hershey Medical Center.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Aggarwal
        </lastname>
        <forename>
         Chander Shekher
        </forename>
        <initials>
         CS
        </initials>
        <affiliationinfo>
         <affiliation>
          University College of Medical Sciences Delhi.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Vunnam
        </lastname>
        <forename>
         Rama Rao
        </forename>
        <initials>
         RR
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Internal Medicine, Penn State Health Milton S. Hershey Medical Center.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Sahu
        </lastname>
        <forename>
         Nitasa
        </forename>
        <initials>
         N
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-4767-9095
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Internal Medicine, Penn State Health Milton S. Hershey Medical Center.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bhatt
        </lastname>
        <forename>
         Dhirisha
        </forename>
        <initials>
         D
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Internal Medicine, Penn State Health Milton S. Hershey Medical Center.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Jones
        </lastname>
        <forename>
         Kirk
        </forename>
        <initials>
         K
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy, Western Maryland Health System, Cumberland, Maryland.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Golamari
        </lastname>
        <forename>
         Reshma
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Internal Medicine, Penn State Health Milton S. Hershey Medical Center.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Jain
        </lastname>
        <forename>
         Rohit
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Internal Medicine, Penn State Health Milton S. Hershey Medical Center.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        07
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       J Am Geriatr Soc
      </medlineta>
      <nlmuniqueid>
       7503062
      </nlmuniqueid>
      <issnlinking>
       0002-8614
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Mortality
      </keyword>
      <keyword majortopicyn="N">
       Older Adults
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        29
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        01
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        8
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        8
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        8
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32255507
      </articleid>
      <articleid idtype="doi">
       10.1111/jgs.16472
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32219356
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       03
      </month>
      <day>
       31
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        2380-6591
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Mar
         </month>
         <day>
          27
         </day>
        </pubdate>
       </journalissue>
       <title>
        JAMA cardiology
       </title>
       <isoabbreviation>
        JAMA Cardiol
       </isoabbreviation>
      </journal>
      <articletitle>
       Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1001/jamacardio.2020.1017
      </elocationid>
      <abstract>
       <abstracttext label="Importance" nlmcategory="UNASSIGNED">
        Increasing numbers of confirmed cases and mortality rates of coronavirus disease 2019 (COVID-19) are occurring in several countries and continents. Information regarding the impact of cardiovascular complication on fatal outcome is scarce.
       </abstracttext>
       <abstracttext label="Objective" nlmcategory="UNASSIGNED">
        To evaluate the association of underlying cardiovascular disease (CVD) and myocardial injury with fatal outcomes in patients with COVID-19.
       </abstracttext>
       <abstracttext label="Design, Setting, and Participants" nlmcategory="UNASSIGNED">
        This retrospective single-center case series analyzed patients with COVID-19 at the Seventh Hospital of Wuhan City, China, from January 23, 2020, to February 23, 2020. Analysis began February 25, 2020.
       </abstracttext>
       <abstracttext label="Main Outcomes and Measures" nlmcategory="UNASSIGNED">
        Demographic data, laboratory findings, comorbidities, and treatments were collected and analyzed in patients with and without elevation of troponin T (TnT) levels.
       </abstracttext>
       <abstracttext label="Result" nlmcategory="UNASSIGNED">
        Among 187 patients with confirmed COVID-19, 144 patients (77%) were discharged and 43 patients (23%) died. The mean (SD) age was 58.50 (14.66) years. Overall, 66 (35.3%) had underlying CVD including hypertension, coronary heart disease, and cardiomyopathy, and 52 (27.8%) exhibited myocardial injury as indicated by elevated TnT levels. The mortality during hospitalization was 7.62% (8 of 105) for patients without underlying CVD and normal TnT levels, 13.33% (4 of 30) for those with underlying CVD and normal TnT levels, 37.50% (6 of 16) for those without underlying CVD but elevated TnT levels, and 69.44% (25 of 36) for those with underlying CVD and elevated TnTs. Patients with underlying CVD were more likely to exhibit elevation of TnT levels compared with the patients without CVD (36 [54.5%] vs 16 [13.2%]). Plasma TnT levels demonstrated a high and significantly positive linear correlation with plasma high-sensitivity C-reactive protein levels (β = 0.530, P &lt; .001) and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels (β = 0.613, P &lt; .001). Plasma TnT and NT-proBNP levels during hospitalization (median [interquartile range (IQR)], 0.307 [0.094-0.600]; 1902.00 [728.35-8100.00]) and impending death (median [IQR], 0.141 [0.058-0.860]; 5375 [1179.50-25695.25]) increased significantly compared with admission values (median [IQR], 0.0355 [0.015-0.102]; 796.90 [401.93-1742.25]) in patients who died (P = .001; P &lt; .001), while no significant dynamic changes of TnT (median [IQR], 0.010 [0.007-0.019]; 0.013 [0.007-0.022]; 0.011 [0.007-0.016]) and NT-proBNP (median [IQR], 352.20 [174.70-636.70]; 433.80 [155.80-1272.60]; 145.40 [63.4-526.50]) was observed in survivors (P = .96; P = .16). During hospitalization, patients with elevated TnT levels had more frequent malignant arrhythmias, and the use of glucocorticoid therapy (37 [71.2%] vs 69 [51.1%]) and mechanical ventilation (41 [59.6%] vs 14 [10.4%]) were higher compared with patients with normal TnT levels. The mortality rates of patients with and without use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers was 36.8% (7 of 19) and 25.6% (43 of 168).
       </abstracttext>
       <abstracttext label="Conclusions and Relevance" nlmcategory="UNASSIGNED">
        Myocardial injury is significantly associated with fatal outcome of COVID-19, while the prognosis of patients with underlying CVD but without myocardial injury is relatively favorable. Myocardial injury is associated with cardiac dysfunction and arrhythmias. Inflammation may be a potential mechanism for myocardial injury. Aggressive treatment may be considered for patients at high risk of myocardial injury.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Guo
        </lastname>
        <forename>
         Tao
        </forename>
        <initials>
         T
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Fan
        </lastname>
        <forename>
         Yongzhen
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         Ming
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wu
        </lastname>
        <forename>
         Xiaoyan
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Lin
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         He
        </lastname>
        <forename>
         Tao
        </forename>
        <initials>
         T
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Hairong
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wan
        </lastname>
        <forename>
         Jing
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Xinghuan
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lu
        </lastname>
        <forename>
         Zhibing
        </forename>
        <initials>
         Z
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        27
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       JAMA Cardiol
      </medlineta>
      <nlmuniqueid>
       101676033
      </nlmuniqueid>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        29
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        29
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        29
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32219356
      </articleid>
      <articleid idtype="pii">
       2763845
      </articleid>
      <articleid idtype="doi">
       10.1001/jamacardio.2020.1017
      </articleid>
      <articleid idtype="pmc">
       PMC7101506
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Proc (Bayl Univ Med Cent). 2018 Oct 26;31(4):419-423
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30948970
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Feb 20;382(8):727-733
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31978945
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2020 Apr;92(4):401-402
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31950516
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2013 Nov 27;310(20):2191-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24141714
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Feb 7;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32031570
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2012 Jun 20;307(23):2526-33
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22797452
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):497-506
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986264
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Sci China Life Sci. 2020 Mar;63(3):457-460
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32009228
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Med. 2005 Aug;11(8):875-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16007097
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Eur J Clin Invest. 2009 Jul;39(7):618-25
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19453650
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Feb 24;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32091533
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Infect Dis. 2020 Feb;91:264-266
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31953166
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Jan 23;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31971553
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32241880
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       08
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       08
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Electronic">
        1756-1833
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         369
        </volume>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          02
         </day>
        </pubdate>
       </journalissue>
       <title>
        BMJ (Clinical research ed.)
       </title>
       <isoabbreviation>
        BMJ
       </isoabbreviation>
      </journal>
      <articletitle>
       Drugs and the renin-angiotensin system in covid-19.
      </articletitle>
      <pagination>
       <medlinepgn>
        m1313
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1136/bmj.m1313
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Aronson
        </lastname>
        <forename>
         Jeffrey K
        </forename>
        <initials>
         JK
        </initials>
        <affiliationinfo>
         <affiliation>
          Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ferner
        </lastname>
        <forename>
         Robin E
        </forename>
        <initials>
         RE
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Clinical Sciences, University of Birmingham, Birmingham, UK.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016421">
        Editorial
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        02
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       BMJ
      </medlineta>
      <nlmuniqueid>
       8900488
      </nlmuniqueid>
      <issnlinking>
       0959-8138
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D057911">
        Angiotensin Receptor Antagonists
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.15.1
       </registrynumber>
       <nameofsubstance ui="C488034">
        ACE protein, human
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.15.1
       </registrynumber>
       <nameofsubstance ui="D007703">
        Peptidyl-Dipeptidase A
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.17.-
       </registrynumber>
       <nameofsubstance ui="C413524">
        angiotensin converting enzyme 2
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      AIM
     </citationsubset>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D057911">
        Angiotensin Receptor Antagonists
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000009">
        adverse effects
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000494">
        pharmacology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000009">
        adverse effects
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000494">
        pharmacology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000187">
        drug effects
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000150">
        complications
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D003657">
        Decision Making
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000081206">
        Duration of Therapy
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006973">
        Hypertension
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007703">
        Peptidyl-Dipeptidase A
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000187">
        drug effects
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000150">
        complications
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D017410">
        Practice Guidelines as Topic
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D012084">
        Renin-Angiotensin System
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000187">
        drug effects
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000502">
        physiology
       </qualifiername>
      </meshheading>
     </meshheadinglist>
     <coistatement>
      Competing interests: JKA is a member of the Centre for Evidence-Based Medicine in Oxford, which jointly runs the EvidenceLive Conference with the BMJ and the Overdiagnosis Conference with some international partners, which are based on a non-profit model. He is an associate editor of BMJ Evidence Based Medicine and was until recently vice-president publications for the British Pharmacological Society. REF was until recently a member of the Birmingham, Sandwell and Solihull Area prescribing committee, is a series editor of The BMJ’s Therapeutic Series, and has an honorary position in University College London. Provenance and peer review: Commissioned; not externally peer reviewed.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        4
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        4
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        9
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32241880
      </articleid>
      <articleid idtype="doi">
       10.1136/bmj.m1313
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32282022
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1538-3598
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        JAMA
       </title>
       <isoabbreviation>
        JAMA
       </isoabbreviation>
      </journal>
      <articletitle>
       Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1001/jama.2020.6019
      </elocationid>
      <abstract>
       <abstracttext label="Importance" nlmcategory="UNASSIGNED">
        The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection.
       </abstracttext>
       <abstracttext label="Observations" nlmcategory="UNASSIGNED">
        No proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug Administration approved and currently is being tested in ongoing randomized trials. Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended. Current clinical evidence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with COVID-19.
       </abstracttext>
       <abstracttext label="Conclusions and Relevance" nlmcategory="UNASSIGNED">
        The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. The speed and volume of clinical trials launched to investigate potential therapies for COVID-19 highlight both the need and capability to produce high-quality evidence even in the middle of a pandemic. No therapies have been shown effective to date.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Sanders
        </lastname>
        <forename>
         James M
        </forename>
        <initials>
         JM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Monogue
        </lastname>
        <forename>
         Marguerite L
        </forename>
        <initials>
         ML
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Jodlowski
        </lastname>
        <forename>
         Tomasz Z
        </forename>
        <initials>
         TZ
        </initials>
        <affiliationinfo>
         <affiliation>
          Pharmacy Service, VA North Texas Health Care System, Dallas.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cutrell
        </lastname>
        <forename>
         James B
        </forename>
        <initials>
         JB
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       JAMA
      </medlineta>
      <nlmuniqueid>
       7501160
      </nlmuniqueid>
      <issnlinking>
       0098-7484
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      AIM
     </citationsubset>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32282022
      </articleid>
      <articleid idtype="pii">
       2764727
      </articleid>
      <articleid idtype="doi">
       10.1001/jama.2020.6019
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      25348530
     </pmid>
     <datecompleted>
      <year>
       2016
      </year>
      <month>
       05
      </month>
      <day>
       15
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2018
      </year>
      <month>
       11
      </month>
      <day>
       13
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1098-6596
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         59
        </volume>
        <issue>
         1
        </issue>
        <pubdate>
         <year>
          2015
         </year>
         <month>
          Jan
         </month>
        </pubdate>
       </journalissue>
       <title>
        Antimicrobial agents and chemotherapy
       </title>
       <isoabbreviation>
        Antimicrob. Agents Chemother.
       </isoabbreviation>
      </journal>
      <articletitle>
       Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2.
      </articletitle>
      <pagination>
       <medlinepgn>
        206-16
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1128/AAC.03999-14
      </elocationid>
      <abstract>
       <abstracttext>
        Endoplasmic reticulum (ER)-resident glucosidases I and II sequentially trim the three terminal glucose moieties on the N-linked glycans attached to nascent glycoproteins. These reactions are the first steps of N-linked glycan processing and are essential for proper folding and function of many glycoproteins. Because most of the viral envelope glycoproteins contain N-linked glycans, inhibition of ER glucosidases with derivatives of 1-deoxynojirimycin, i.e., iminosugars, efficiently disrupts the morphogenesis of a broad spectrum of enveloped viruses. However, like viral envelope proteins, the cellular receptors of many viruses are also glycoproteins. It is therefore possible that inhibition of ER glucosidases not only compromises virion production but also disrupts expression and function of viral receptors and thus inhibits virus entry into host cells. Indeed, we demonstrate here that iminosugar treatment altered the N-linked glycan structure of angiotensin I-converting enzyme 2 (ACE2), which did not affect its expression on the cell surface or its binding of the severe acute respiratory syndrome coronavirus (SARS-CoV) spike glycoprotein. However, alteration of N-linked glycans of ACE2 impaired its ability to support the transduction of SARS-CoV and human coronavirus NL63 (HCoV-NL63) spike glycoprotein-pseudotyped lentiviral particles by disruption of the viral envelope protein-triggered membrane fusion. Hence, in addition to reducing the production of infectious virions, inhibition of ER glucosidases also impairs the entry of selected viruses via a post-receptor-binding mechanism.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2015, American Society for Microbiology. All Rights Reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Zhao
        </lastname>
        <forename>
         Xuesen
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Drexel Institute for Biotechnology and Virology Research, Department of Microbiology and Immunology, Drexel University College of Medicine, Doylestown, Pennsylvania, USA Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Guo
        </lastname>
        <forename>
         Fang
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Drexel Institute for Biotechnology and Virology Research, Department of Microbiology and Immunology, Drexel University College of Medicine, Doylestown, Pennsylvania, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Comunale
        </lastname>
        <forename>
         Mary Ann
        </forename>
        <initials>
         MA
        </initials>
        <affiliationinfo>
         <affiliation>
          Drexel Institute for Biotechnology and Virology Research, Department of Microbiology and Immunology, Drexel University College of Medicine, Doylestown, Pennsylvania, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Mehta
        </lastname>
        <forename>
         Anand
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Drexel Institute for Biotechnology and Virology Research, Department of Microbiology and Immunology, Drexel University College of Medicine, Doylestown, Pennsylvania, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Sehgal
        </lastname>
        <forename>
         Mohit
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Drexel Institute for Biotechnology and Virology Research, Department of Microbiology and Immunology, Drexel University College of Medicine, Doylestown, Pennsylvania, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Jain
        </lastname>
        <forename>
         Pooja
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Drexel Institute for Biotechnology and Virology Research, Department of Microbiology and Immunology, Drexel University College of Medicine, Doylestown, Pennsylvania, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cuconati
        </lastname>
        <forename>
         Andrea
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lin
        </lastname>
        <forename>
         Hanxin
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Block
        </lastname>
        <forename>
         Timothy M
        </forename>
        <initials>
         TM
        </initials>
        <affiliationinfo>
         <affiliation>
          Drexel Institute for Biotechnology and Virology Research, Department of Microbiology and Immunology, Drexel University College of Medicine, Doylestown, Pennsylvania, USA Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chang
        </lastname>
        <forename>
         Jinhong
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Drexel Institute for Biotechnology and Virology Research, Department of Microbiology and Immunology, Drexel University College of Medicine, Doylestown, Pennsylvania, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Guo
        </lastname>
        <forename>
         Ju-Tao
        </forename>
        <initials>
         JT
        </initials>
        <affiliationinfo>
         <affiliation>
          Drexel Institute for Biotechnology and Virology Research, Department of Microbiology and Immunology, Drexel University College of Medicine, Doylestown, Pennsylvania, USA Ju-Tao.Guo@drexelmed.edu.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <grantlist completeyn="Y">
       <grant>
        <grantid>
         R01 CA054559
        </grantid>
        <acronym>
         CA
        </acronym>
        <agency>
         NCI NIH HHS
        </agency>
        <country>
         United States
        </country>
       </grant>
       <grant>
        <grantid>
         U01 CA168856
        </grantid>
        <acronym>
         CA
        </acronym>
        <agency>
         NCI NIH HHS
        </agency>
        <country>
         United States
        </country>
       </grant>
       <grant>
        <grantid>
         R01 CA120206
        </grantid>
        <acronym>
         CA
        </acronym>
        <agency>
         NCI NIH HHS
        </agency>
        <country>
         United States
        </country>
       </grant>
       <grant>
        <grantid>
         R01 AI104636
        </grantid>
        <acronym>
         AI
        </acronym>
        <agency>
         NIAID NIH HHS
        </agency>
        <country>
         United States
        </country>
       </grant>
       <grant>
        <grantid>
         AI104636
        </grantid>
        <acronym>
         AI
        </acronym>
        <agency>
         NIAID NIH HHS
        </agency>
        <country>
         United States
        </country>
       </grant>
      </grantlist>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D052061">
        Research Support, N.I.H., Extramural
       </publicationtype>
       <publicationtype ui="D013485">
        Research Support, Non-U.S. Gov't
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2014
       </year>
       <month>
        10
       </month>
       <day>
        27
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Antimicrob Agents Chemother
      </medlineta>
      <nlmuniqueid>
       0315061
      </nlmuniqueid>
      <issnlinking>
       0066-4804
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000998">
        Antiviral Agents
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C585142">
        CM-10-18 compound
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D004791">
        Enzyme Inhibitors
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C000600715">
        IHVR-11029
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C000600716">
        IHVR-17028
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D050111">
        Imino Sugars
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D064370">
        Spike Glycoprotein, Coronavirus
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C578559">
        spike glycoprotein, human coronavirus (HCV)
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.2.1.-
       </registrynumber>
       <nameofsubstance ui="D005959">
        Glucosidases
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.15.1
       </registrynumber>
       <nameofsubstance ui="D007703">
        Peptidyl-Dipeptidase A
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.17.-
       </registrynumber>
       <nameofsubstance ui="C413524">
        angiotensin converting enzyme 2
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000998">
        Antiviral Agents
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000737">
        chemistry
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000494">
        pharmacology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058957">
        Coronavirus NL63, Human
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000187">
        drug effects
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000472">
        pathogenicity
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D004721">
        Endoplasmic Reticulum
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000187">
        drug effects
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D004791">
        Enzyme Inhibitors
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000737">
        chemistry
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000494">
        pharmacology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D005959">
        Glucosidases
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000037">
        antagonists &amp; inhibitors
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D054884">
        Host-Pathogen Interactions
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000187">
        drug effects
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D050111">
        Imino Sugars
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000737">
        chemistry
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000494">
        pharmacology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058990">
        Molecular Targeted Therapy
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007703">
        Peptidyl-Dipeptidase A
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000737">
        chemistry
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D045473">
        SARS Virus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000187">
        drug effects
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000472">
        pathogenicity
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D064370">
        Spike Glycoprotein, Coronavirus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D053586">
        Virus Internalization
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000187">
        drug effects
       </qualifiername>
      </meshheading>
     </meshheadinglist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2014
       </year>
       <month>
        10
       </month>
       <day>
        29
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2014
       </year>
       <month>
        10
       </month>
       <day>
        29
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2016
       </year>
       <month>
        5
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       25348530
      </articleid>
      <articleid idtype="pii">
       AAC.03999-14
      </articleid>
      <articleid idtype="doi">
       10.1128/AAC.03999-14
      </articleid>
      <articleid idtype="pmc">
       PMC4291352
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2000 Feb;45(2):135-47
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         10809022
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):913-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         8302866
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Antiviral Res. 2002 Jul;55(1):151-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12076759
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Nature. 2003 Nov 27;426(6965):450-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14647384
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        J Biol Chem. 2004 Jan 30;279(5):3197-201
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14670965
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Antiviral Res. 1988 Nov;10(1-3):11-26
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         2852915
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        J Virol. 2008 Feb;82(4):1665-78
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18077728
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        J Gen Virol. 2008 Apr;89(Pt 4):1015-24
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18343844
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2009 Apr;53(4):1501-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19223639
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Antiviral Res. 2009 Jun;82(3):95-102
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19428599
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 1994 Aug;38(8):1780-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         7986008
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Virology. 1995 Feb 1;206(2):935-44
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         7531918
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        J Virol. 1995 Sep;69(9):5791-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         7543588
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        J Virol. 1995 Nov;69(11):6705-11
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         7474080
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        J Virol. 1996 Oct;70(10):7143-52
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         8794361
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        J Virol. 1996 Oct;70(10):7153-60
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         8794362
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Anal Biochem. 1996 Sep 5;240(2):210-26
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         8811911
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1822-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         9050863
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Glycobiology. 1998 Jul;8(7):725-30
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         9621113
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18153-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15601777
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2005 May 31;102(22):7988-93
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15897467
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        J Virol. 2005 Jul;79(14):8698-706
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15994763
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        J Virol. 2005 Oct;79(20):12914-20
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16188993
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        J Biol Chem. 2006 Feb 10;281(6):3198-203
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16339146
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        J Gen Virol. 2006 Apr;87(Pt 4):861-71
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16528036
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Adv Exp Med Biol. 2006;581:335-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17037556
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Hepatology. 2007 Apr;45(4):921-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17393519
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Antiviral Res. 2007 Oct;76(1):30-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17548120
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Curr Opin Investig Drugs. 2009 Aug;10(8):860-70
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19649930
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19970-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19901337
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Virology. 2010 Apr 10;399(2):257-69
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20129637
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Cell Host Microbe. 2010 Jun 25;7(6):427-39
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20542247
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        J Virol. 2010 Aug;84(16):8332-41
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20534863
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Curr Drug Discov Technol. 2010 Jun;7(2):86-94
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20836760
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Antiviral Res. 2011 Jan;89(1):26-34
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21073903
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2011 Mar;55(3):1036-44
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21173177
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Virus Res. 2011 Sep;160(1-2):283-93
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21798295
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Antiviral Res. 2011 Dec;92(3):453-60
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22020302
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Curr Opin Pulm Med. 2012 May;18(3):271-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22366993
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        FASEB J. 2012 Apr;26(4):1372-86
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22247330
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        J Med Chem. 2012 Jul 12;55(13):6061-75
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22712544
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Curr Opin Immunol. 2012 Aug;24(4):438-43
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22770666
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Antiviral Res. 2012 Oct;96(1):32-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22867971
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        J Virol. 2012 Nov;86(21):11745-53
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22915798
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Curr Opin Virol. 2012 Oct;2(5):606-13
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23025912
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2012 Dec;56(12):6379-86
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23070155
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Annu Rev Pathol. 2013 Jan 24;8:411-40
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23121052
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Bioorg Med Chem Lett. 2013 Apr 1;23(7):2172-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23453839
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Antiviral Res. 2013 Apr;98(1):35-43
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23376501
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Antiviral Res. 2013 Jun;98(3):432-40
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23578725
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Antiviral Res. 2013 Jul;99(1):68-77
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23578729
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Biochem Biophys Res Commun. 2013 Jul 5;436(3):394-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23747419
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Cell Mol Life Sci. 2013 Aug;70(15):2799-814
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23503623
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Antiviral Res. 2013 Sep;99(3):251-60
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23816430
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Trends Pharmacol Sci. 2014 Feb;35(2):86-102
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24439476
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        N Engl J Med. 2014 Apr 24;370(17):1615-25
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24716661
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2014 May 6;111(18):6756-61
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24753610
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        J Biol Chem. 1992 Jun 5;267(16):11573-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         1317871
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        J Acquir Immune Defic Syndr. 1994 Feb;7(2):139-47
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         7905523
        </articleid>
       </articleidlist>
      </reference>
      <reference>
       <citation>
        J Virol. 2002 Apr;76(8):3596-604
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         11907199
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32081428
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       03
      </month>
      <day>
       26
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1090-2104
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Feb
         </month>
         <day>
          17
         </day>
        </pubdate>
       </journalissue>
       <title>
        Biochemical and biophysical research communications
       </title>
       <isoabbreviation>
        Biochem. Biophys. Res. Commun.
       </isoabbreviation>
      </journal>
      <articletitle>
       Structure analysis of the receptor binding of 2019-nCoV.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       S0006-291X(20)30339-9
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.bbrc.2020.02.071
      </elocationid>
      <abstract>
       <abstracttext>
        2019-nCoV is a newly identified coronavirus with high similarity to SARS-CoV. We performed a structural analysis of the receptor binding domain (RBD) of spike glycoprotein responsible for entry of coronaviruses into host cells. The RBDs from the two viruses share 72% identity in amino acid sequences, and molecular simulation reveals highly similar ternary structures. However, 2019-nCoV has a distinct loop with flexible glycyl residues replacing rigid prolyl residues in SARS-CoV. Molecular modeling revealed that 2019-nCoV RBD has a stronger interaction with angiotensin converting enzyme 2 (ACE2). A unique phenylalanine F486 in the flexible loop likely plays a major role because its penetration into a deep hydrophobic pocket in ACE2. ACE2 is widely expressed with conserved primary structures throughout the animal kingdom from fish, amphibians, reptiles, birds, to mammals. Structural analysis suggests that ACE2 from these animals can potentially bind RBD of 2019-nCoV, making them all possible natural hosts for the virus. 2019-nCoV is thought to be transmitted through respiratory droplets. However, since ACE2 is predominantly expressed in intestines, testis, and kidney, fecal-oral and other routes of transmission are also possible. Finally, antibodies and small molecular inhibitors that can block the interaction of ACE2 with RBD should be developed to combat the virus.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         Yun
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Edmond H. Fischer Translational Medical Research Laboratory, Precision Medicine Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Guo
        </lastname>
        <forename>
         Yao
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Edmond H. Fischer Translational Medical Research Laboratory, Precision Medicine Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Pan
        </lastname>
        <forename>
         Yihang
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Edmond H. Fischer Translational Medical Research Laboratory, Precision Medicine Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China. Electronic address: yihang73@hotmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhao
        </lastname>
        <forename>
         Zhizhuang Joe
        </forename>
        <initials>
         ZJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Edmond H. Fischer Translational Medical Research Laboratory, Precision Medicine Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China; Department of Pathology, University of Oklahoma Health Sciences Center, 940 Stanton L. Young Blvd, Oklahoma City, OK, 73104, USA. Electronic address: joe-zhao@ouhsc.edu.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        17
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Biochem Biophys Res Commun
      </medlineta>
      <nlmuniqueid>
       0372516
      </nlmuniqueid>
      <issnlinking>
       0006-291X
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Molecular modeling
      </keyword>
      <keyword majortopicyn="N">
       Sequence analysis
      </keyword>
      <keyword majortopicyn="N">
       Structure analysis
      </keyword>
     </keywordlist>
     <coistatement>
      Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        06
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        10
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        2
       </month>
       <day>
        22
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        2
       </month>
       <day>
        23
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        2
       </month>
       <day>
        23
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32081428
      </articleid>
      <articleid idtype="pii">
       S0006-291X(20)30339-9
      </articleid>
      <articleid idtype="doi">
       10.1016/j.bbrc.2020.02.071
      </articleid>
      <articleid idtype="pmc">
       PMC7092824
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19970-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19901337
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2003 Oct 10;302(5643):276-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12958366
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Med. 2019 Jul;25(7):1153-1163
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31209336
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Future Microbiol. 2011 Feb;6(2):153-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21366416
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biochem Biophys Res Commun. 2004 Apr 2;316(2):476-83
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15020242
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        EMBO J. 2005 Apr 20;24(8):1634-43
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15791205
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Pathol. 2004 Jun;203(2):631-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15141377
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2005 Sep 16;309(5742):1864-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16166518
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Med. 2004 Apr;10(4):368-73
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15034574
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biochemistry. 2003 Nov 18;42(45):13185-92
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14609329
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2005 Dec;79(24):15511-24
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16306622
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 1998 Jun 19;273(25):15458-63
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         9624131
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Annu Rev Virol. 2016 Sep 29;3(1):237-261
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27578435
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2003 Nov 27;426(6965):450-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14647384
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2013 Nov 28;503(7477):535-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24172901
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Curr Hypertens Rep. 2017 Sep 19;19(10):80
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28929450
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Hypertension. 2004 Dec;44(6):903-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15492138
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cardiovasc Res. 2007 Feb 1;73(3):463-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17049503
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2430-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15695582
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Methods Mol Biol. 2015;1282:1-23
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25720466
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
  </pubmedarticleset>
 </body>
</html>